Your browser doesn't support javascript.
Cardiologic evaluation of Turkish mitochondrial fatty acid oxidation disorders.
Balci, Mehmet Cihan; Karaca, Meryem; Ergul, Yakup; Omeroglu, Rukiye Eker; Demirkol, Mubeccel; Gokcay, Gulden Fatma.
  • Balci MC; Division of Pediatric Nutrition and Metabolism, Istanbul Medical Faculty Children's Hospital, Istanbul University, Istanbul, Turkey.
  • Karaca M; Division of Pediatric Nutrition and Metabolism, Istanbul Medical Faculty Children's Hospital, Istanbul University, Istanbul, Turkey.
  • Ergul Y; Division of Pediatric Cardiology, Istanbul Medical Faculty Children's Hospital, Istanbul University, Istanbul, Turkey.
  • Omeroglu RE; Division of Pediatric Cardiology, Istanbul Medical Faculty Children's Hospital, Istanbul University, Istanbul, Turkey.
  • Demirkol M; Division of Pediatric Nutrition and Metabolism, Istanbul Medical Faculty Children's Hospital, Istanbul University, Istanbul, Turkey.
  • Gokcay GF; Division of Pediatric Nutrition and Metabolism, Istanbul Medical Faculty Children's Hospital, Istanbul University, Istanbul, Turkey.
Pediatr Int ; 64(1): e15317, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-2251024
ABSTRACT

BACKGROUND:

Mitochondrial fatty acid oxidation disorders (FAODs) cause impairment in energy metabolism and can lead to a spectrum of cardiac pathologies including cardiomyopathy and arrhythmias. The frequency of underlying cardiac pathologies and the response to recommended treatment in FAODs was investigated.

METHODS:

Sixty-eight children (35 males, 33 females) with the diagnosis of a FAOD were included in the study. Cardiac function was evaluated with 12-lead standard electrocardiography, echocardiography, and 24 h Holter monitoring.

RESULTS:

Forty-five patients (66%) were diagnosed after disease symptoms developed and 23 patients (34%) were diagnosed in the pre-symptomatic period. Among symptomatic patients (n 45), cardiovascular findings were detected in 18 (40%) patients, including cardiomyopathy in 14 (31.1%) and conduction abnormalities in 4 (8.8%) patients. Cardiac symptoms were more frequently detected in primary systemic carnitine deficiency (57.1%). Patients with multiple acyl-CoA dehydrogenase, long-chain 3-hydroxyacyl-CoA dehydrogenase, and mitochondrial trifunctional protein deficiencies also had an increased frequency of cardiac symptoms. Patients with medium-chain acyl-CoA dehydrogenase, very long-chain acyl-CoA dehydrogenase, and carnitine palmitoyltransferase I deficiencies had a lower prevalence of cardiac symptoms both during admission and during clinical follow up. Cardiomyopathy resolved completely in 8/14 (57%) patients and partially in 2/14 (14.3%) patients with treatment. Two patients with cardiomyopathy died in the newborn period; cardiomyopathy persisted in 1 (7.1%) patient with very long-chain acyl-CoA dehydrogenase deficiency.

CONCLUSION:

Early diagnosis, treatment and follow up made a significant contribution to the improvement of cardiac symptoms of patients with FAODs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Mitochondrial Diseases / Lipid Metabolism, Inborn Errors / Cardiomyopathies Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Child / Female / Humans / Male / Infant, Newborn Language: English Journal: Pediatr Int Journal subject: Pediatrics Year: 2022 Document Type: Article Affiliation country: Ped.15317

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Mitochondrial Diseases / Lipid Metabolism, Inborn Errors / Cardiomyopathies Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Child / Female / Humans / Male / Infant, Newborn Language: English Journal: Pediatr Int Journal subject: Pediatrics Year: 2022 Document Type: Article Affiliation country: Ped.15317